| Preface | 5 |
---|
| Contents | 7 |
---|
| Contributors | 9 |
---|
| Evolutionary Trends in Body Size | 14 |
---|
| Summary | 14 |
| Introduction | 14 |
| Body size trends | 17 |
| Identifying trends | 18 |
| Body size and diversity | 24 |
| Human impacts | 27 |
| Conclusions | 28 |
| Acknowledgements | 29 |
| References | 29 |
| Sexual Dimorphism in the Growth of Homo sapiens: Facts, Inferences and Speculation | 32 |
---|
| Summary | 32 |
| Introduction | 32 |
| Sexual dimorphism in primates | 33 |
| Sexual dimorphism in H. sapiens | 35 |
| Molecular and biochemical basis for dimorphic growth | 36 |
| References | 38 |
| Genetic Control of Size at Birth | 40 |
---|
| Summary | 40 |
| Introduction | 41 |
| Maternal uterine environment | 42 |
| Maternal genes and size at birth | 43 |
| Fetal genes and size at birth | 45 |
| Conclusions | 47 |
| References | 49 |
| The GH/ IGF- 1 Axis: Insights from Animal Models | 54 |
---|
| Summary | 54 |
| Introduction | 54 |
| Insulin- like pathways control growth | 56 |
| Somatotrope control of IGF and growth | 57 |
| IGF- 1R mutations in mice | 59 |
| Overview | 62 |
| References | 62 |
| Downstream Mechanisms of Growth Hormone Action | 66 |
---|
| Summary | 66 |
| Introduction | 66 |
| JAK2 is essential for initiating GHR signaling | 68 |
| MAPK- ERK1/2 pathway in GHR signaling | 68 |
| Role of PI3K-AKT pathway in GH action | 69 |
| Critical role of STAT5b in mediating GH action | 69 |
| Conclusions | 72 |
| References | 74 |
| Growth Hormone Receptor Signaling and Differential Actions in Target Tissues Compared to IGF- I | 78 |
---|
| Summary | 78 |
| Introduction | 79 |
| Receptors and Signaling Pathways | 79 |
| JAK STAT Pathway | 80 |
| MAP Kinase Pathway | 80 |
| Other Pathways | 81 |
| Bone Development and the Somatomedin Hypothesis Revisited | 82 |
| Muscle Growth And Differentiation | 86 |
| References | 87 |
| IGF- I and Brain Growth: Multifarious Effects on Developing Neural Cells and Mechanisms of Action | 90 |
---|
| Summary | 90 |
| Introduction | 90 |
| IGF- I Transgenic and Gene- Targeted Mice | 91 |
| Diverse functions of IGF- I on multiple neural cell types | 92 |
| Mechanisms and Signaling Pathways for IGF- I Actions on Neural Cells | 96 |
| The PI3- Kinase Pathway and IGF Actions in the Brain | 99 |
| Conclusions | 102 |
| References | 102 |
| IGF- I Deficiency: Lessons from Human Mutations | 108 |
---|
| Summary | 108 |
| Introduction | 108 |
| IGF- I gene mutations | 109 |
| Other mutations in the GH- IGF- I axis causing IGF- I deficiency and GH insensitivity | 112 |
| Conclusions | 115 |
| References | 116 |
| Putting IGF- I Biology into a Clinical Perspective | 120 |
---|
| Introduction | 120 |
| IGF Parameters for the Diagnosis of GH Deficiency | 121 |
| Monitoring IGF- I levels on GH treatment | 122 |
| Cross-sectional Survey of IGF Monitoring | 126 |
| Conclusions | 127 |
| References | 131 |
| IGF Resistance: The Role of the Type 1 IGF Receptor | 134 |
---|
| Summary | 134 |
| Introduction | 135 |
| References | 141 |
| The Importance of the National Cooperative Growth Study ( NCGS) | 144 |
---|
| Introduction | 144 |
| History | 144 |
| The NCGS Today | 145 |
| NCGS Substudies | 146 |
| NCGS Targeted Events | 147 |
| Importance of the NCGS: Conclusions | 149 |
| References | 149 |
| Appendix 1 | 150 |
| Why we are Treating Children with Growth Hormone: Lessons from the French Registry | 156 |
---|
| Summary | 156 |
| Introduction | 156 |
| Conclusion | 162 |
| Acknowledgments | 162 |
| References | 162 |
| Subject Index | 166 |